Overview
Patient-Centered Approaches to Treatment and Prevention of Clostridioides difficile Infection
Live/Virtual symposium
Registration is closed for this activity.
Join Dr. Feuerstadt and Dr. Khanna as they review the latest data and clinical approaches to Clostridioides difficile infection (CDI). Patient cases will be included to guide clinical decisions on the selection of therapy for initial and recurrent CDI.
This activity is intended for gastroenterologists, infectious disease specialists, primary care physicians, advanced practice providers and other clinicians who care for patients with initial and recurrent Clostridioides difficile infection
C. difficile infection (CDI) continues to be a threat. Guideline recommendations on the selection of antimicrobial therapy for treating initial and recurrent CDI have changed. Are you up to date on these advances? Join Dr. Feuerstadt and Dr. Khanna as they review the latest data and clinical approaches. Patient cases will be included to guide clinical decisions on the selection of therapy for initial and recurrent CDI.
Upon completion of this activity, participants will be able to:
• Discuss the selection of antimicrobials considerate of their impact on gut microbiota
• Assess available and updated clinical guidelines to ensure evidence-based therapeutic selection for treatment of initial infection and prevention of recurrent CDI
• Describe clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
• Discuss the selection of antimicrobials considerate of their impact on gut microbiota
• Assess available and updated clinical guidelines to ensure evidence-based therapeutic selection for treatment of initial infection and prevention of recurrent CDI
• Describe clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Merck & Co., Inc.
Paul Feuerstadt, MD, FACG, AGAF
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Sahil Khanna, MBBS, MS, FACG
Professor of Medicine
Director, C. difficile Clinic and Microbiome Restoration Therapy Program
Director, Comprehensive Gastroenterology Interest Group
Mayo Clinic
Rochester, MN
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Paul Feuerstadt, MD, FACG, AGAF
Consulting Agreements: Ferring Pharmaceuticals, Roche Diagnostics, Seres Therapeutics, Takeda Pharmaceuticals
Speakers' Bureau: Merck and Co.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational microbiota restoration therapies
Sahil Khanna, MBBS, MS, FACG
Sources of Funding for Grant/Research: Finch Therapeutics, Pfizer, Rebiotx/Ferring, Seres Therapeutics, Vedanta
Consulting Agreements: Immuron, Jetson, Niche, ProBioTech, Shire/Takeda,
Stockholder: Jetson
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
To receive credit, participants are required to participate in the live activity and complete the posttest, and evaluation. Once the posttest and evaluation are completed, a certificate will be immediately available and also emailed. There is no fee to participate in the activity or for the generation of the certificate.
When using a certificate code:
To receive credit:
1. Go to www.ACHLcme.org
2. Click on “Use Certificate Code”
3. Enter the Certificate Code provided at the end of the session
4. Complete the posttest and evaluation, and your certificate will be immediately available to you.
Participants will receive an automated certificate. You may print or save this record for your files. It will also be sent to you via email to the address provided in your profile on www.ACHLcme.org. There is no fee to participate in the activity or for the generation of the certificate.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 160.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The Academy for Continued Healthcare Learning designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
